• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[马垂体腺瘤的临床症状及诊断可能性]

[Clinical symptoms of and diagnostic possibilities for hypophyseal adenoma in horses].

作者信息

Feige K, Eser M W, Geissbühler U, Balestra E, Metzler K

机构信息

Klinik für Wiederkäuer- und Pferdemedizin, Universität Zürich.

出版信息

Schweiz Arch Tierheilkd. 2000 Feb;142(2):49-54.

PMID:10697998
Abstract

Hirsutism was the most often observed symptom in horses with a pituitary gland tumor and was present in all 13 examined horses. Other symptoms were atrophy of muscles (n = 10), hyperhidrosis (n = 8), polyuria/polydipsia (n = 5), bulging or supraorbital fat (n = 3), polyphagia (n = 2), apathy (n = 2) and seizures (n = 2). Laminitis was the most frequently observed concurrent disease (n = 8). Hyperglycaemia (mean, 9.9 +/- 3.71 mmol/l) in 13 horses and glucosuria (median, 55 [range, 2-55] mmol/l) in 7 horses were the most important laboratory results. The dexamethasone suppression test was positive in all tested horses (n = 9) 20 h after administration of dexamethasone. The pituitary gland tumor was visible in every case underwent computed tomography (n = 7). From these results it can be concluded that a pituitary gland tumor can be suspected based on typical clinical signs. Hyperglycaemia and glucosuria support the preliminary diagnosis and a positive dexamethasone suppression test allows a final diagnosis.

摘要

多毛症是患有垂体肿瘤马匹中最常观察到的症状,在所有13匹接受检查的马匹中均有出现。其他症状包括肌肉萎缩(n = 10)、多汗症(n = 8)、多尿/多饮(n = 5)、眶上脂肪突出(n = 3)、多食(n = 2)、冷漠(n = 2)和癫痫发作(n = 2)。蹄叶炎是最常观察到的并发疾病(n = 8)。13匹马出现高血糖(平均,9.9 +/- 3.71 mmol/l),7匹马出现糖尿(中位数,55 [范围,2 - 55] mmol/l)是最重要的实验室检查结果。地塞米松抑制试验在所有受试马匹(n = 9)给予地塞米松20小时后均呈阳性。在每例接受计算机断层扫描的病例(n = 7)中均可见垂体肿瘤。从这些结果可以得出结论,基于典型的临床症状可怀疑垂体肿瘤。高血糖和糖尿支持初步诊断,而地塞米松抑制试验阳性则可确诊。

相似文献

1
[Clinical symptoms of and diagnostic possibilities for hypophyseal adenoma in horses].[马垂体腺瘤的临床症状及诊断可能性]
Schweiz Arch Tierheilkd. 2000 Feb;142(2):49-54.
2
Results of a combined dexamethasone suppression/thyrotropin-releasing hormone stimulation test in healthy horses and horses suspected to have a pars intermedia pituitary adenoma.健康马匹和疑似患有垂体中间部腺瘤的马匹的地塞米松抑制/促甲状腺激素释放激素刺激联合试验结果。
J Am Vet Med Assoc. 1997 Jul 1;211(1):79-81.
3
Clinical snapshot: Hirsutism in a pony.临床快照:一匹小马的多毛症
Compend Contin Educ Vet. 2013 Mar;35(3):E6.
4
Adrenocorticotropin-containing neoplastic cells in a pars intermedia adenoma in a horse.一匹马的中间部腺瘤中含促肾上腺皮质激素的肿瘤细胞。
J Am Vet Med Assoc. 1988 Feb 1;192(3):367-71.
5
Adenoma of the pars intermedia and hirsutism in a pony.
Vet Med Small Anim Clin. 1978 Sep;73(9):1197-200.
6
Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia.促甲状腺激素释放激素给药后,健康马匹以及患有垂体中间部功能障碍和垂体增生马匹的促肾上腺皮质激素浓度。
J Am Vet Med Assoc. 2007 Aug 1;231(3):417-26. doi: 10.2460/javma.231.3.417.
7
Equine pituitary neoplasia: a clinical report of 21 cases (1990-1992).
Vet Rec. 1993 Dec 11;133(24):594-7.
8
Immunocytochemical localization of adrenocorticotropic hormone-immunoreactive cells of the pars intermedia in thoroughbreds.纯种马垂体中间部促肾上腺皮质激素免疫反应细胞的免疫细胞化学定位
Am J Vet Res. 1997 Aug;58(8):920-4.
9
Laboratory diagnosis of equine pituitary pars intermedia adenoma.
Domest Anim Endocrinol. 1995 Jan;12(1):35-9. doi: 10.1016/0739-7240(94)00006-m.
10
Lipid metabolism in horses with hyperadrenocorticism.患有肾上腺皮质功能亢进的马匹的脂质代谢
J Am Vet Med Assoc. 1995 Apr 1;206(7):1010-2.

引用本文的文献

1
Association Between Adrenocorticotropic Hormone Concentration and Clinical Signs of Pituitary Pars Intermedia Dysfunction in Swiss and Austrian Equids.瑞士和奥地利马属动物促肾上腺皮质激素浓度与垂体中间部功能障碍临床体征之间的关联
J Vet Intern Med. 2025 Mar-Apr;39(2):e70008. doi: 10.1111/jvim.70008.